Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J R Foster

Showing results (201-210 of 205) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 205 results.
Cancer Discovery|November 7, 2020
Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian CancerShuang Zhang, Sonia Iyer, Hao Ran, et al.
Toxicologic Pathology|June 23, 2012
Liver hypertrophy: a review of adaptive (adverse and non-adverse) changes--conclusions from the 3rd International ESTP Expert WorkshopA P Hall, C R Elcombe, J R Foster, et al.
British Journal of Clinical Pharmacology|January 24, 2019
Population pharmacokinetics of lenalidomide in patients with B-cell malignanciesJim H Hughes, Mitch A Phelps, Richard N Upton, et al.
Cancer Chemotherapy and Pharmacology|August 31, 2002
A phase I study of the GM-CSF antagonist E21RIan N Olver, Tim Hercus, Angel Lopez, et al.
The Journal of Experimental Medicine|October 12, 2020
SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodelingCarmine Fedele, Shuai Li, Kai Wen Teng, et al.
Pageof 21

Showing results (201-210 of 205) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 205 results.
Cancer Discovery|November 7, 2020
Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian CancerShuang Zhang, Sonia Iyer, Hao Ran, et al.
Toxicologic Pathology|June 23, 2012
Liver hypertrophy: a review of adaptive (adverse and non-adverse) changes--conclusions from the 3rd International ESTP Expert WorkshopA P Hall, C R Elcombe, J R Foster, et al.
British Journal of Clinical Pharmacology|January 24, 2019
Population pharmacokinetics of lenalidomide in patients with B-cell malignanciesJim H Hughes, Mitch A Phelps, Richard N Upton, et al.
Cancer Chemotherapy and Pharmacology|August 31, 2002
A phase I study of the GM-CSF antagonist E21RIan N Olver, Tim Hercus, Angel Lopez, et al.
The Journal of Experimental Medicine|October 12, 2020
SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodelingCarmine Fedele, Shuai Li, Kai Wen Teng, et al.
Pageof 21